Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Johnson & Johnson's diversified MedTech and pharma mix faces off against Vertex's cystic fibrosis dominance, but their valuation gap tells a story worth weighing.

In a comparison of Johnson & Johnson versus Vertex Pharmaceuticals for potential investment in 2027, the healthcare landscape presents distinct opportunities and risks for each company.

Johnson & Johnson, a diversified healthcare giant, is making strategic pivots towards its innovative medical and MedTech segments, which are projected to drive global growth. The company's revenue of approximately $99.3 billion in the last fiscal year reflects a 7.8% increase compared to the previous period, with net income reaching about $16.1 billion.

Key collaborations include a license for the drug Darzalex and a partnership with AbbVie for co-commercializing Imbruvica. Despite facing legal risks related to product liability and intellectual property challenges, Johnson & Johnson maintains a balanced financial position with a debt-to-equity ratio of roughly 0.6x and a current ratio of nearly 1.0x.

The company's free cash flow of around $19.7 billion in the last fiscal year indicates ample capital for research and dividends.

On the other hand, Vertex Pharmaceuticals, a specialized biotechnology leader, is successfully diversifying its pipeline beyond its core treatments in cystic fibrosis. The company reported revenue of about $13.0 billion in the last fiscal year, marking a 10.5% growth rate compared to the previous year, with net income at approximately $4.0 billion.

Vertex's aggressive expansion into gene-editing and acute pain therapies, along with partnerships like the one with CRISPR Therapeutics, positions it well in the market. The company maintains a conservative debt-to-equity ratio of about 0.1x and a strong current ratio of roughly 2.9x, suggesting robust short-term financial health.

However, Vertex faces risks related to high revenue concentration in its cystic fibrosis franchise and intense competition in the biotechnology sector, along with uncertainties in regulatory approval and manufacturing for its advanced therapies.

valuation-wise, Johnson & Johnson appears to be undervalued compared to Vertex Pharmaceuticals, given its lower valuation multiples and a robust portfolio of over 28 products and platforms. The company's diversified product line and strong revenue streams position it favorably for future growth. Conversely, Vertex's reliance on its cystic fibrosis franchise presents both opportunities for continued success and challenges related to pricing pressures and competition.

Overall, investors should weigh the diversified and stable financial profile of Johnson & Johnson against the high-growth potential and innovation-driven strategy of Vertex Pharmaceuticals when deciding which healthcare stock might be a better buy for 2027.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Every outlet that reported this, and when →

Read the original at fool.com →

More in Finance & Markets

More from Tuesday 17 November →